NZ233795A - Derivatives of atrial natriuretic peptide (anp) - Google Patents
Derivatives of atrial natriuretic peptide (anp)Info
- Publication number
- NZ233795A NZ233795A NZ233795A NZ23379590A NZ233795A NZ 233795 A NZ233795 A NZ 233795A NZ 233795 A NZ233795 A NZ 233795A NZ 23379590 A NZ23379590 A NZ 23379590A NZ 233795 A NZ233795 A NZ 233795A
- Authority
- NZ
- New Zealand
- Prior art keywords
- arg
- cys
- gly
- ile
- phe
- Prior art date
Links
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical class C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 claims description 148
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 90
- 150000001875 compounds Chemical class 0.000 claims description 89
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 150000001408 amides Chemical class 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 108010016626 Dipeptides Proteins 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 9
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 claims description 9
- 108010018625 phenylalanylarginine Proteins 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- SITWEMZOJNKJCH-WDSKDSINSA-N Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SITWEMZOJNKJCH-WDSKDSINSA-N 0.000 claims description 4
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- VPZXBVLAVMBEQI-VKHMYHEASA-N Glycyl-alanine Chemical compound OC(=O)[C@H](C)NC(=O)CN VPZXBVLAVMBEQI-VKHMYHEASA-N 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 claims description 3
- SENJXOPIZNYLHU-IUCAKERBSA-N Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-IUCAKERBSA-N 0.000 claims description 3
- 108010079364 N-glycylalanine Proteins 0.000 claims description 3
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 3
- XZKQVQKUZMAADP-IMJSIDKUSA-N Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(O)=O XZKQVQKUZMAADP-IMJSIDKUSA-N 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 108010000761 leucylarginine Proteins 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000010189 synthetic method Methods 0.000 claims description 3
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical group OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims description 2
- 206010048962 Brain oedema Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 208000006752 brain edema Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000004880 Polyuria Diseases 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 230000035619 diuresis Effects 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 137
- 235000001014 amino acid Nutrition 0.000 description 135
- 229920005989 resin Polymers 0.000 description 113
- 239000011347 resin Substances 0.000 description 113
- QJCNLJWUIOIMMF-YUMQZZPRSA-N (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C QJCNLJWUIOIMMF-YUMQZZPRSA-N 0.000 description 94
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 81
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 61
- 239000000843 powder Substances 0.000 description 57
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 55
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 55
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 54
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 54
- 238000004458 analytical method Methods 0.000 description 54
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 53
- 239000007788 liquid Substances 0.000 description 53
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 51
- 125000004122 cyclic group Chemical group 0.000 description 48
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 43
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 42
- -1 Asp-Arg-Ile Chemical class 0.000 description 32
- 150000003857 carboxamides Chemical class 0.000 description 31
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 239000002934 diuretic Substances 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 229910052708 sodium Inorganic materials 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 11
- 229920001367 Merrifield resin Polymers 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- DMBKPDOAQVGTST-GFCCVEGCSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylmethoxypropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)COCC1=CC=CC=C1 DMBKPDOAQVGTST-GFCCVEGCSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010011732 Cyst Diseases 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 208000031513 cyst Diseases 0.000 description 7
- 229960004717 insulin aspart Drugs 0.000 description 7
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- 230000001882 diuretic effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001452 natriuretic effect Effects 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- 208000001953 Hypotension Diseases 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 208000021822 hypotensive Diseases 0.000 description 5
- 230000001077 hypotensive effect Effects 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 230000001084 renoprotective effect Effects 0.000 description 5
- 230000002883 vasorelaxation effect Effects 0.000 description 5
- YQAXFVHNHSPUPO-RNJOBUHISA-N 2-[[(2s)-2-[[2-[[(2s,4r)-1-[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]acetic acid Chemical class OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H]1N(C(=O)CN)CCC1 YQAXFVHNHSPUPO-RNJOBUHISA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 4
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 108010006835 Atrial Natriuretic Factor Receptors Proteins 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000050 smooth muscle relaxant Substances 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HMQDRBKQMLRCCG-GMOBBJLQSA-N Asp-Arg-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HMQDRBKQMLRCCG-GMOBBJLQSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 201000004239 Secondary hypertension Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 1
- CMJCWQISQGNHHI-ZETCQYMHSA-N (2s)-5-(carbamoylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCNC(N)=O CMJCWQISQGNHHI-ZETCQYMHSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- ZNCXJJQGNNRNPR-UHFFFAOYSA-N 2-amino-4-nitrophenol;hydrochloride Chemical compound Cl.NC1=CC([N+]([O-])=O)=CC=C1O ZNCXJJQGNNRNPR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- HHGYNJRJIINWAK-FXQIFTODSA-N Ala-Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N HHGYNJRJIINWAK-FXQIFTODSA-N 0.000 description 1
- SDMAQFGBPOJFOM-GUBZILKMSA-N Ala-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SDMAQFGBPOJFOM-GUBZILKMSA-N 0.000 description 1
- SKHCUBQVZJHOFM-NAKRPEOUSA-N Ala-Arg-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SKHCUBQVZJHOFM-NAKRPEOUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- XBQSLMACWDXWLJ-GHCJXIJMSA-N Asp-Ala-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O XBQSLMACWDXWLJ-GHCJXIJMSA-N 0.000 description 1
- OERMIMJQPQUIPK-FXQIFTODSA-N Asp-Arg-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O OERMIMJQPQUIPK-FXQIFTODSA-N 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- VTTSANCGJWLPNC-ZPFDUUQYSA-N Glu-Arg-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VTTSANCGJWLPNC-ZPFDUUQYSA-N 0.000 description 1
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 1
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- JBJNKUOMNZGQIM-PYJNHQTQSA-N His-Arg-Ile Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JBJNKUOMNZGQIM-PYJNHQTQSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- IUWMQCZOTYRXPL-ZPFDUUQYSA-N Lys-Ile-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O IUWMQCZOTYRXPL-ZPFDUUQYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 101000823982 Panax ginseng Squalene synthase 1 Proteins 0.000 description 1
- GLUBLISJVJFHQS-VIFPVBQESA-N Phe-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-VIFPVBQESA-N 0.000 description 1
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- SSSDKJMQMZTMJP-BVSLBCMMSA-N Trp-Tyr-Val Chemical compound C([C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 SSSDKJMQMZTMJP-BVSLBCMMSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- GCFAUZGWPDYAJN-UHFFFAOYSA-N cyclohexyl 3-phenylprop-2-enoate Chemical compound C=1C=CC=CC=1C=CC(=O)OC1CCCCC1 GCFAUZGWPDYAJN-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical compound [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002031 ethanolic fraction Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- YYTWEEOFRNSTKS-UHFFFAOYSA-N n,n'-dicyclohexylmethanediimine;1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1CCCCC1N=C=NC1CCCCC1 YYTWEEOFRNSTKS-UHFFFAOYSA-N 0.000 description 1
- 239000002833 natriuretic agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
- 108010072906 phosphoramidon Proteins 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000012175 toxemia of pregnancy Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
New Zealand Paient Spedficaiion for Paient Number £33795 233795 Priority Daiai.-} Convents F.'-v.': C:ass: G)-C5.7.\Is?>.kf..
Publication ....
P.O. v»cy«7!?!. No: 2 3 JUL 8» .I55«, HQ DRAWING: NEW ZEALAND PATENTS ACT, J953 No.: Date: COMPLETE SPECIFICATION ATRIAL PEPTIDE DERIVATIVES "if We, ABBOTT LABORATORIES, a corporation organized and existing under the laws of the State of Illinois, USA of One Abbott Park Road, Abbott Park Illinois, 60064-3500, United States of America hereby declare the invention for which -£-/ we pray that a patent may be granted to me-/us, and the method by which it is to be performed, to be particularly described in and by the following statement: - 23 3 7 -la- ATRIAL PEPTIDE DERIVATIVES Technical Field The present invention relates to derivatives of atrial natriuretic polypeptides (ANP) which exhibit useful hypotensive, natriuretic, diuretic, renovasodilating, renoprotective, vasorelaxant and smooth muscle relaxant activity.
Background of the Invention Heretofore, hypertension has been classified as either hypertension having clear factor disease or hypertension having obscure factor disease. Hypertension having clear factor disease is also known as secondary hypertension and involves mainly hypertension caused by kidney disease, endocrine disease, toxemia of pregnancy, arterial embolism, atherosclerosis, central nervous system disease and the like. The conditions of secondary hypertension can be improved by treatment of the factor disease.
However, eighty to ninety per cent of all hypertensive patients suffer from hypertension having obscure factor disease, commonly known as essential hypertension. The treatment of patients having essential hypertention has been affected by agents such as hypotensive diuretics or vasodilators which provide symptomatic relief. With these antihypertensive agents side effects, including lightheadedness, fatique, nausea, respiratory distress, • headache, palpitations, depression and impotence are common.
Recently, alpha-human atrial polypeptide (alpha-hANP) has been isolated from human atrium and identified as a 23 3 7 9 polypeptide consisting of twenty eight amino acids having the following formula: Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg- S S Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr Alpha-hANP is a peptide hormone which reacts with specific receptors on the plasma membrane of cells in target tissues and effects a number of hemodynamic and metabolic events in humans. It has been suggested that the above alpha-hANP is one of the substances involved in the control of hypertension, congestive heart failure, cirrhosis, renal failure, cerebral edema and the maintenance of normal extracellular fluid volume. It has also been reported that the diuretic action of alpha-hANP is about 1000 times as strong as that of furosemide which is used as a hypotensive diuretic.
Others have found that alpha-hANP increases urinary sodium concentration and urinary output.
Known analogs of alpha-hANP have been reported to show biological potency that correlates well with their affinity for the alpha-hANP receptors (Jacobs, J.W.; Vlasuk, G.P.; Rosenblatt, M. Endocrinology and Metabolism Clinics of North America, 16, 63-77 (1987)). However, alpha-hANP or derivatives thereof which are chemically and enzymatically stable and have therapeutically useful potency and duration of action have not been commercially available. For this reason, the search for alpha-hANP derivatives with these favorable properties has been actively pursued. In addition, it is considered desirable to prepare analogs of ANP in order to isolate the regions of ANP responsible for binding to the cellular plasma membrane receptor and also for eliciting subsequent 233795 biological activities mediated via receptor occupation. U.S. Patent No. 4,757,048 discloses alpha-hANP analogs which vary in size from 8 to 25 amino acid residues. The compounds of the present invention are distinctly different from these prior art compounds in several important aspects, specifically in their amino acid sequences and in their ability to elicit receptor-mediated synthesis of cGMP. Additionally, there are no known analogs of ANP which are characterized by incorporation within the disulfide ring of a truncated C-terminal amino acid sequence as described in the present invention.
Summary of the Invention In accordance with the present invention, novel peptides are provided which exhibit useful hypotensive, natriuretic, diuretic, renovasodilating, reno-protective, smooth muscle relaxant and vasorelaxant activities. The compounds of the invention include biologically active peptides having the following amino acid sequence: S S R1-R2-R3-R4-R5-R6-R7-R8 (Formula I) or a pharmaceutically acceptable salt, ester or amide thereof.
In the above formula, R* is selected from hydrogen, AcetylArg, Aha, Arg, Cit, His, Lys, Orn and Ser-Ser; 2 .
R is a sulfur-containing group; 3 R is a hydrophobic amino acid or dipeptide; 233795 4 R is a dipeptide spacer, or a tripeptide containing a dipeptide spacer plus a basic amino acid residue; R^ is a hydrophobic amino acid; g R is a peptide of up to three amino acids; 7 R is selected from Cha, Phe, Cha-Arg, Phe-Arg, (D)Phe-Arg, Phe-(D)Arg, Phe—Arg, Leu-Arg, Ala-Arg, Arg and Gly-Ala; and g R is a sulfur-containing group.
The present invention also relates to the use of the atrial peptide derivatives of formula (I) in the treatment of ANP-related diseases.
The invention further relates to compositions comprising a therapeutically effective amount of the polypeptide of formula (I) and a pharmaceutically acceptable carrier or diluent.
Detailed Description of the Invention The present invention provides novel peptides which exhibit useful hypotensive, natriuretic, diuretic, renovasodilating, reno-protective, smooth muscle relaxant and vasorelaxant activities. The compounds of the invention comprise peptides having the following amino acid sequence: S S R1—R2-R3-R4-R5-R6-R7-R8 (Formula I) or a pharmaceutically acceptable salt, ester or amide thereof, 233795 wherein R1 is selected from hydrogen, AcetylArg, Aha, Arg, Cit, His, Lys, Orn and Ser-Ser, and is preferably hydrogen 2 (when R is Mpa) or a basic amino acid; 2 . .
R is a sulfur-containing group; R3 is a hydrophobic amino acid or dipeptide, examples of which include Phe, (D)Phe, (D)Cha, Pic, Phe-Gly, Phg, (D)Phg, Cha, Chg, Cha-(D)Ala, (D)Ala-Cha, Arg-Cha, Tic and 3,5-diiodoTyr (3,5-l2Tyr), and is preferably a hydrophobic amino acid containing a cycloalkyl group; 4 R is a dipeptide spacer such as Gly-Gly or (D)Ala-Ala, or a tripeptide of the formula X-Y where X is a dipeptide spacer and Y is a basic amino acid, as for example Gly-Gly-Arg, Gly-Gly-(D)Arg, Gly-Gly-Lys, Gly-Arg-Arg, (D) Ala-Arg-Arg, (D)Ala-Ala-Arg and (D)Ala-(D)Ala-Arg; is a hydrophobic amino acid; £ R is a peptide of up to three amino acids, such as Asp-Arg-Ile, (D)Asp-Arg-Ile, Asp-Arg-(D)lie, pAsp-Arg-Ile, Asp-Arg- Ala, Asp-Arg-Nva, Asp-Ala-Ile, Glu-Arg-Ile, His-Arg-Ile or Ala-Arg-Ile; 7 R is selected from Cha, Phe, Cha-Arg, Phe-Arg, (D)Phe-Arg, Phe-(D)Arg, Phe^Arg, Leu-Arg, Ala-Arg, Arg and Gly-Ala; and 8 R is a sulfur-containing group.
The methods of the present invention comprise the use of atrial peptide derivatives of formula (I) in the treatment of 233795 ANP-related diseases including, for example, congestive heart failure, renal failure and hypertension.
The pharmaceutical compositions of the invention include compositions comprising a therapeutically effective amount of a polypeptide of formula (I) and a pharmaceutical^ acceptable carrier or diluent.
Representative of the preferred compounds of this invention include the following polypeptides, as well as their pharmaceutically acceptable salts, esters and amides: Arg-Cys-Cha- (D)Ala-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Ser-Ser-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Cha-Arg-Cys; Arg-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-(D)Ala-Cha-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Cha-Gly-Gly-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Cys-Arg-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-(D)Ala-Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; 23 3795 Arg-Cys-Tic-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Phe-Gly-Gly-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; His-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Orn-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; AcetylArg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Cit-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Cys-NH2; Arg-Cys-3,5-l2Tyr-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Lys-Ile-Asp-Arg-Ile-Phe-Arg-Cvs-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-(D)Asp-Arg-Ile-Phe-Arg-Cys-NH2; (D)Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Chg-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; \ 23 37 95 Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ala-Phe-Arg-Cys-NH2; Arg-Cys-(D)Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Ala-Arg-Ile-Ala-Arg-Cys; Mpa-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Pic-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Cys-Cha-Gly-Glv-Arg-Ile-(D)Asp-Arg-Ile-Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ala^Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Ala-Ile-Phe-Arg-Cys-NH2; Mpa-Cha-Gly-Gly-Arg-Ile-beta-Asp-Arg-lle-Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-(D)Ile-Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Nva-Asp-Arg-Nva-Phe-Arg-Cys-NH2; Cys-(D)Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Mpa-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-(D)Arg-Cys-NH2; Mpa-Cha-Gly-Gly-Arg-lle-Asp-Arg-Ile-Phe-Arg-(D)Cys-NH2; Mpa-Cha-(D)Ala-Arg-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; 233795 Cys-Phe-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Leu-Arg-Cys-NH2 ; Mpa-Cha-Gly-Gly-Arg-Ile-Glu-Arg-Ile-Phe-Arg-Cys-NK2; Mpa-Cha-Gly-Gly-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2 ; Mpa-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-(D)Phe-Arg-Cys-NH2; Aha-Cys-Cha-(D)Ala-(D)Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Mpa-Cha-Gly-Gly-Arg-Ile-His-Arg-Ile-Phe-Arg-Cys-NH2; Mpa-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Mpa-Cha-(D)Ala-Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-(D)Cys-NH2; and Mpa-Cha-(D) Ala-Ala-Arg-Ile-Asp-Arg-Ile- [Phe^Arg] - (D) Cys-NH2 .
Preferred compounds of this invention include the following polypeptides, as well as their pharmaceutically acceptable salts, esters and amides: Ser-Ser-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Cha-Arg-Cys; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Cys-Arg-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; 23 37 95 Arg-Cys-Cha-(D)Ala-Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; His-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-CyS-NH2/ Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Lys-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; (D)Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp—Arg-Ile-Phe-Arg—Cys—NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ala-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Ala-Arg-Ile-Ala-Arg-Cys; Mpa-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ala-Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-(D)Ile-Phe-Arg-Cys-NH2; Cys-(D)Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Mpa-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-(D)Cys-NH2; Mpa-Cha-(D)Ala-Arg-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Aha-Cys-Cha-(D)Ala-(D)Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; 233795 -li- Mpa-Cha-Gly-Gly-Arg-Ile-Glu-Arg-Ile-Phe-Arg-Cys-NH2; and Mpa-Cha- (D) Ala-Ala-Arg-Ile-Asp-Arg-Ile- [Phe^Arg] - (D) Cys-NH2 .
The amino acid components of the above compounds are designated by conventional abbreviations as follows: Amino Acid Abbreviated Designation One Letter Code Alanine Ala A 6-Aminohexanoic acid Aha Aminoisobutyric acid Aib Arginine Arg R Aspartic acid Asp D Citrulline Cit Cyclohexylalanine Cha Cyclohexylglycine Chg Cysteine Cys C Glutamic acid Glu E Glycine Gly G Histidine His H a-Homocysteine hCys Isoleucine He I Leucine Leu L Lysine Lys K Mercaptopropionic acid Mpa Methionine Met M Norvaline Nva Ornithine Orn Penicillamine Pen Phenylalanine Phe F 23 37 Amino Acid Abbreviated Designation One Letter Code Phenylalanyl-Arginine reduced amide (Na[1-(2-amino-3-phenyl- propyl)]arginine) Phenylglycine Per-Hydroindane carboxylic acid Serine Tetrahydroisoquinoline- [ Phe-Arg] Phg Pic Ser S 3-carboxylic acid Tryptophan Tyrosine Valine Tic Trp Tyr Val W V Y All of the above amino acids can be either in the L or £ configuration as well as mixtures thereof including a racemic mixture of the two isomers. Unless expressly stated otherwise, all of the amino acids are optically active and have the L-configuration.
The term "AcetylArg" as used herein refers to a group wherein an acetyl group is attached through the carbonyl carbon of the acetyl group to the alpha amino group of the amino acid arginine.
The term "acidic amino acid" as used herein refers to amino acids which have a group, in addition to the alpha-carboxylic acid group, which exists in ionized form in neutral aqueous solution, as for example Asp, Glu and the like.
The term "basic amino acid" as used herein refers to amino acids which have a group, in addition to the alpha-amino group, which exists in protonated form in neutral aqueous solution, as for example Lys, Orn, Arg and the like. 233795 The term "cycloalkyl" as used herein refers to a three to seven carbon cyclic radical. These radicals can be unsubstituted, or they can be substituted provided that any such substituents not interfere with the affinity of the peptide for atrial natriuretic polypeptide receptors.
The term "hydrophobic amino acid" as used herein refers to amino acids which lack an affinity for water, such as Ala, lie, Leu, Val, Met, Nva, Phe, Phg, Cha, Chg, Tic, and the like.
The term "sulfur-containing group" as used herein refers to a group having a sulfur substituent which is available to participate in bonding to form a disulfide bridge, as for example Cys, Mpa, Pen and hCys.
By "pharmaceutically acceptable salts, esters, or amides" it is meant those salts, esters and amides which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use. Examples of pharmaceutically acceptable, nontoxic addition salts are salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid. Other pharmaceutically acceptable salts include nitrate, bisulfate, formate, valerate, lactate, fumarate, oleate, palmitate, stearate, laurate, borate, benzoate, mesylate, ascorbate, p-toluene-sulfonate, glucoheptonate, lactobioate, lauryl sulfate and the like or metal salts such as sodium, potassium, calcium or magnesium salts or amino salts such as ammonium, triethylamine salts, and the like and they may be prepared according to conventional methods. \ 23 37 Examples of pharmaceutically acceptable, non-toxic esters of the compounds of Formula (I) include CI to C6 alkyl esters wherein the alkyl group is straight or branched chain. Acceptable esters also include C5 to C7 cycloalkyl esters. CI to C4 alkyl esters are preferred. Esters of the compounds of Formula (I) may be prepared according to conventional methods.
Examples of pharmaceutically acceptable, nontoxic amides of the compounds of Formula (I) include amides derived from ammonia, primary CI to C6 alkyl amines and secondary CI to C6 dialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines the amine may also be in the form of a five or six membered heterocycle containing one nitrogen atom. Amides derived from ammonia, CI to C3 alkyl primary amines and CI to C2 dialkyl secondary amines are preferred. Amides of the compounds of Formula (I) are prepared according to the conventional methods.
The daily dose of the compounds of the present invention may be suitably defined, according to the condition of the patient, by those skilled in the art, but generally may be administered in an amount of 0.2 - 250 mg/kg body weight.' Unit dosage compositions may contain such amounts of submultiples thereof to make up the daily dose.
The amount of active ingredient that may may be combined with carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the route of administration and the rate of excretion of the specific compound; drug combination used ana the severity of the particular disease being treated. 23 3795 The compounds of the present invention may be administered orally, parenterally, by inhalation spray, rectally or topically in unit dosage formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants and vehicles as desired. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
Injectable preparations, as for example sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, as for example a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycol which are solid at ordinary temperature but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
Solid dosage forms for oral administration may include capsules, tablets, pills, powders and granules. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, as for example lubricating agents such as magnesium stearate. In the 23 3795 case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art such as water. Such compositions may also comprise adjuvants, such as wetting agents; emulsifying and suspending agents; and sweetening, flavoring and perfuming agents.
The novel polypeptides and salts thereof of the invention can be utilized effectively as vasorelaxant agents, diuretics, natriuretic agents, renovasodilators or renoprotective agents. Accordingly the present invention further relates to vasorelaxant, diuretic, natriuretic, renovasodilating or renoprotective compositions comprising a novel polypeptide having the general formula (I) or salts thereof as an active component.
The polypeptides of the invention may be prepared by the synthetic method of elongation of a peptide chain through condensation of one amino acid by one, or several amino acids, or by a combination of these methods in accordance with conventional peptide synthesis methods.
The condensation of two amino acids, the condensation of an amino acid with a peptide or the condensation of one peptide with another peptide may be effected in accordance with conventional condensation methods such as the azide method, the mixed acid anhydride method, the DCC (dicyclohexylcarbodiimide) method, the active ester method (p-nitrophenyl ester method, N-hydroxysuccinic acid imide ester method, cyanomethyl ester method and the like), the Woodward reagent K method, the DCC-HOBT (1-hydroxy-benzotriazole) method and the like. These condensation reactions may be done by either solution methods or solid phase synthetic methods. 233795 When the peptide chain is elongated by solid phase methods, the C-terminal amino acid is linked to an insoluble carrier. Any insoluble carrier may be used which can produce a detachable bond by reacting with a carboxyl group in a C-terminal amino acid, as for example halomethyl resins such as chloromethyl or bromomethyl resins; hydroxymethyl resin; aminomethyl resin; benzhydrylamine resin and t-alkyloxycarbonyl hydrazide resin.
As in conventional polypeptide synthesis, branched chain amino and carboxyl groups at alpha and omega positions in amino acids may be protected and deprotected if necessary. The protecting groups for amino groups which can be used involve, for example, benzyloxycarbonyl (Z), o-chloro- benzyloxycarbonyl((2-C1)Z) , p-nitrobenzyloxycarbonyl (Z(N02>), p-methoxybenzyloxycarbonyl (Z(OMe)), t-butoxycarbonyl (Boc), t-amyloxycarbonyl (Aoc) , isobornealoxycarbonyl, adamantyloxycarbonyl (Adoc), 2-(4-biphenyl)-2-propyloxy carbonyl (Bpoc), 9-fluorenyl-methoxycarbonyl (Fmoc), methylsulfonylethoxy carbonyl (Msc), trifluoroacetyl, phthalyl, formyl, 2-nitrophenylsulfenyl (Nps), diphenylphosphinothioyl (Ppt) and dimethylphosphino-thioyl (Mpt) .
The examples of protecting groups for carboxyl groups involve, for example, benzyl ester (OBzl), cyclohexyl ester, 4-nitrobenzyl ester (OBZINO2) , t-butyl ester (OtBu), 4-pyridylmethyl ester (OPic) and the like.
In the course of the synthesis of the following peptides, specific amino acids having functional groups other than amino and carboxyl groups in the branched chain such as arginine, cysteine, serine and the like may be protected, if necessary, with suitable protecting groups. It is preferable that, for example, the guanidino group (N ) in arginine may be protected with nitro, p-toluenesulfonyl (Tos), benzyloxycarbonyl (Z), 23 37 adamantyloxycarbonyl (Adoc), p-methoxybenzenesulfonyl, 4-methoxy-2,6-dimethyl-benzenesulfonyl (Mts) and the like, and the thiol group in cysteine may be protected with benzyl, p-methoxybenzyl, triphenylmethyl, acetamidomethyl, ethylcarbamyl, 4-methylbenzyl (4-MeBzl), 2,4,6,-trimethylbenzyl (Tmb) and the like, and the hydroxy group in serine may be protected with benzyl (Bzl), t-butyl, acetyl, tetrahydropyranyl {THP) and the like.
The compounds of the invention are prepared by standard solid phase peptide synthesis conditions as described in "Solid Phase Peptide Synthesis" by John M Stewart and Janis D. Young, Second Edition (1984) and illustrated in Examples 1 and 2 in the experimental section.
The compounds of the invention may also be prepared by partial solid phase synthesis, fragment condensation methods and classical solution methods as exemplified by the methods described in "Peptide Synthesis", Second Edition, M. Bodansky, Y.S. Klausner and M.A. Ondetti (1976).
The foregoing may be better understood by reference to the following examples which are provided for illustration and not limitation of the practice of the invention.
Example 1 Arainyl (N^-Tos) -Cysteir.vl (4-MeBzl) -Cyclohexylalanvl- (D) - Q Alanyl-Glycyl-Glycyl-Arqinyl (N -Tos) -Leucyl-Aspart-yl (beta-cyclohexyl>-Arainyl(N^-Tos)-Isoleucyl-Phenvlalanvl-Arainvl Q (N -Tos) -Cysteiny1-p-MethyIbenz'nvdrvlamine Prot.scr.ed Peptide Resin.
Resin (p-methylbenzhydrylamine functionalized styrene-divinylbenzene copolymer, 0.5 g, commercially available from Bachem, Inc.) was placed in a solid phase peptide synthesis 233795 vessel and amino acids were attached to the peptide resin sequentially in the following order: Boc-Cys(4-MeBzl), Boc- G G Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Boc-Asp(beta- Q cyclohexyl), Boc-Leu, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc- G (D)Ala, Boc-Cha, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), according to the protocol outlined in Agenda A to yield the protected peptide resin: Arginyl-Cysteinyl(4-MeBzl)-Cyclohexylalanyl- r* (D)Alanyl-Glycyl-Glycyl-Arginyl(N -Tos)-Leucyl-Aspartyl(beta- G G cyclohexyl)-Arginyl(N -Tos)-Isoleucyl-Phenylaianyl-Arginyl(N - Tos)-Cysteinyl(4-MeBzl)-p-Methylbenzhydrylamine resin.
Following the synthesis, the protected peptide was removed from the reaction vessel by washing the resin three times with mL N,N-dimethyl formamide (DMF) into a 60 mL sintered glass funnel, followed by washing the resin three times with 30 mL methylene chloride (CH2CI2) . The resin was dried in vacuo for three hours, then weighed.
Agenda A 1. Deblock: 50% Trifluoroacetic acid (TFA) in CI^C^ containing 2% Anisole, 0.5% Ethanedithiol (v/v/v). 2. Neutralization: 10% Diisopropylethylamine: (DIEA) in CH2CI2 (v/v). 3. Single Coupling: 0.2 U Boc-amino acid derivative in DMF, 0.2 M diisopropylcarbodiimide in CH2Cl2r reaction time 60 minutes. 4. Resin Clean Up: 10% DIEA in CH2CI2• . Single Coupling: 0.2 m Boc-amino acid derivative (same as Step 3) in DMF; 0.2 M diisopropylcarbodiimide in CH2CI2/ reaction time 60 min. 6. Cap: 0.3 M Acetylimidazole in DMF. 7. Go to next amino acid residue. 233795 8. Upon attachment of the final amino acid to the growing peptide chain, the protecting group (t-Boc) is removed as in Step 1.
Example. 2 Aran nyl-Cysteinyl-Cyclohexylalar.yl- (D)Alanyl-Glycyl-Glycyl-Ara inyl-Leuc vl-Aspart vl-Arqir.vl-Isoleucyl-Pheny la lanyl-Arainyl-CysteinyI Carboxamide Cyclic Disulfide.
Protected resin (0.50 g) of Example 1 was treated with 1.3 mL anisole and 13 mL liquid hydrogen fluoride (HF) for 60 O minutes at 0 C. The HF and anisole were removed from the resin in vacuo and the resin was washed, under a nitrogen atmosphere, with 2 X 25 mL portions of diethyl ether or ethyl acetate. The crude peptide was extracted from the resin by treatment with 6 X 50 mL portions of deoxygenated 20% aqueous acetic acid. The acetic acid solution was diluted to 1.5 L with distilled water and the pH of the solution was adjusted to about 7.2 using concentrated ammonium hydroxide. The solution was oxidized with 17 mL of 0.01N iodine solution (in ethanol). The resultant yellow solution was stirred for 60 minutes at room temperature while the pH was maintained at about 7.2. The excess iodine was removed from the solution by first adjusting the pH to about 5.5 with 50 mL glacial acetic acid and then adding 3-6 mL of 0.0IN sodium thiosulfate solution. The combined aqueous solution was applied to a column containing 300 g XAD-16 molecular adsorbent resin (commercially available from Rohm and Haas Company). The sample was desalted by first washing the column with 3 L distilled water. The sample was eluted from the column with 1.5 L 50% aqueous ethanol. The combined ethanol fractions were concentrated to approximately 100 mL in vacuo, taken up in an 233795 additional 100 mL distilled water ar.d lyophilized to a dry amorphous powder. The dry powder was purified by High Performance Liquid Chromatography (HPLC) using 0.1% aqueous trifluoroacetic acid (TFA) and acetonitrile as organic modifiers. The preparative HPLC was performed using a Dynamax (RAININ) Cis reverse-phase column (2.1 cm i.d. X 25 cm) at a flow rate of 12-15 mL/min. The sample was purified by linear solvent-gradient elution from 10% acetonitrile/90% aq. solvent (0.1% TFA in H2O) to 35% acetonitrile/65% aqueous solvent. Analytical HPLC was performed using a VYDAC 218 TP 10 micron Cis reverse-phase column (0.46 cm i.d. X 20 cm). There was obtained 2.5 mg of the title compound as a white powder.
Amino acid Analysis: Ala (1.1), Arg (4.0), Asp (1.1), Cha (0.9), Cys (1.4), Gly (2.2), lie (1.2) Leu (1.2), Phe (1.2) .
FAB (M+H)+ at M/Z: 1672.
The 300 MHz *H NMR spectrum was found to be consistent with the proposed structure.
Example 3 Servl-Seryl-Cysteinyl-Cyclohexylalanyl-Glycyl-Glycyl-Arainy1-Isoleucvl-Aspartvl-Aralnvl-Isoleucvl-Phenylalanvl-Arainvl- Cyst.einyl Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from Boc-Cys(4-MeBzl)-0- Merrifield resin (commercially available from 3achem, Inc.) and the amino acids Q added sequentially in the following order: Boc-Arg(N -Tos), Q Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Boc-Asp(beta-cyclohexyl), Q Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys (4-MeBzl), Boc-Ser(Bzl), Boc-Ser(Bzl), was treated with HF \ 233795 (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 17 mg.
Amino Acid Analysis: Arg (3.0), Asp (1.0), Cys (0.8), Gly (2.1), lie (2.0), Phe (1.0), Ser (2.0).
FAB (M+H)+ at M/Z: 1621.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 4 Sftrvl-Sfrryl-Cvst-einvl-rvclohexvlalanvl-Glvcvl-Glvcvl-Arqinvl-Isoleucyl-Aspart.yl-Arainyl-Isoleucyl-Cvclohexylalanvl-Arqinvl- Cysteinyl Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from Boc-Cys(4-MeBzl)-O-Merrifield resin and the amino acids added sequentially in the following order: Boc- G G Arg(N -Tos), Boc-Cha, Boc-Ile, Boc-Arg(N -Tos), Boc-Asp(beta- r> cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), Boc-Ser(Bzl), Boc-Ser(Bzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 18.1 mg.
Amino Acid Analysis: Arg (3.0), Asp (1.0), Cha (2.0), Cys (1.5), Gly (2.0), lie (2.0), Ser (1.5).
FAB (M+H)+ at M/Z: 1628.
The 300 MHz *H spectrum was found to be consistent with the proposed structure. 233795 Example 5 Arg i ny 1-Cy sr. einyl-Phenyl alanvl-Gl ycvl-Givevl-Arginvl-Isoleucyl-Asparf.y l-Arqinyl-Isoleucyl -Phenvlalanyl-Arainyl-Cyst.piny 1 Carbnxamide Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- c c MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(beta—cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Q Boc-Gly, Boc-Phe, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 15 mg.
Amino Acid Analysis: Arg (3.9), Asp (0.9), Cys (1.8), lie (2.1), Gly (1.9), Phe (2.0).
FAB (M+H)+ at M/Z: 1597.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 6 Arainvl-Cysteinyl - (D)Alanyl-Cyclohexylalanvl-Glvcvl-Glvcvl-Arqinyl-Leucyl-Aspartyl-Arqinvl-Isoleucvl-Phenvlalanvi-Arginyl-Cysteinyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- C* G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), r* Boc-Asp(beta-cyclohexyl), Boc-Leu, Boc-Arg(N -Tos), Boc-Gly, 0 Boc-Gly, Boc-Cha, Boc-(D)Ala, Boc-Cys(4-MeBzl) , Boc-Arg(N - 233795 Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 15 mg.
Amino Acid Analysis: Ala (0.9), Arg (4.1), Asp (0.9), Cha (1.0), Cys (1.7), Gly (2.0), lie (1.1), Leu (1.1), Phe (1.0) .
FAB (M+H)+ at M/Z: 1672.
The 300 MHz ^H NMR spectrum was found to be consistent with the proposed structure.
Example 7 Arainyl-Cysteinyl-Cyclohexvlalanyl-Glycvl-Glycvl-Arqinyl-Tsolencvl -Aspartvl-Arcriny l-Isoleucyl-Phe»ny1 alanvl -Arcri nvl- Cysteinyl Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from Boc-Cys(4-MeBzl)-O-Merrifield resin and the amino acids added sequentially in the following order: Boc- G G Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Boc-Asp (beta- n cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc- Q Cha, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 13 mg.
Amino Acid Analysis: Arg (4.1), Asp (1.0), Cha (1.0), Cys (1.9), Gly (1.9), lie (2.0), Phe (1.0).
FAB (M+H)+ at M/Z: 1604.
The 300 MHz ^H NMR spectrum was found to be consistent with the proposed structure. \ 23 3795 Example 8 Seryl-SeryI-Cysteinyl-Cyclohexylalany1-Glycvl-Glycy1-(D) -Arginyl-Tsoleucyl-Asparf.y 1-Arai. nvl-Isoleucvl-Phenylalanvl-Arainyl-Cysteinyl Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from Boc-Cys(4-MeBzl)-O-Merrifield resin and the amino acids added sequentially in the following order: Boc- G G Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Boc-Asp(beta- p cyclohexyl), Boc-Ile, Boc-(D)Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), Boc-Ser(Bzl), Boc-Ser(Bzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 17.5 mg.
Amino Acid Analysis: Arg (3.2), Asp (1.0), Cha (0.9), Cys (1.8), Gly (1.9), lie (2.0), Phe (0.9), Ser (1.4). FAB (M+H)+ at M/Z: 1620.
The 300 MHz 1H NMR spectrum was found to be consistent with the proposed structure. axample 9 Cysteinyl-Cyclohexylalanyl-Glycyl-G] yr.yl -Arqinvl-Isoleucvl-Aspartyl-Arginyl-Isoleucy1-Phenylalanvl-Arqinvl-Cvsteinvl Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from Boc-Cys(4-MeBzl)-O-Merrifield resin and the amino acids added sequentially in the following order: Boc-Arg(N^-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N^-Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), was treated with HF (liquid) and 233795 purified as described in Example 2. The title compound was obtained as a white powder, 25.1 mg.
Amino Acid Analysis: Arg (3.0), Asp (1.0), Cha (1.0), Cys (1.7), Gly (2.1), lie (2.0), Phe (1.0).
FAB (M+H)+ at M/Z: 1446.
The 300 MHz ^H NMR spectrum was found to be consistent with the proposed structure.
Example 10 Cvst.e in vl-Arai nv l-Cvcl ohexv 1 a 1 any1 -G1 vcvl-Glvcvl-Arcrinvl-Isoleucyl-Aspartyl-Arainyl-Tsolencyl-Phenylalanvl-Arainvl- Cysteinyl Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from Boc-Cys(4-MeBzl)-O-Merrifield resin and the amino acids added sequentially in the following order: Boc- c c Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Boc-Asp(beta- G cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc- r* Cha, Boc-Arg(N -Tos), Boc-Cys(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 18 mg.
Amino Acid Analysis: Arg (3.9), Asp (0.9), Cha (1.0), Cys (0.6), Gly (2.1), lie (2.0), Phe (1.0).
FAB (M+H)+ at M/Z: 1602.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure. 2 3 3 7 0 5 Example 11 Arpinyl-Cysteinyl-Cvr1ohexvlalanvl-Glycyl-Glycyl-Arginvl-Tsoleucyl-Aspartyl-Aralny1-Isoleucyl-PhenyI alariyl-Arqinvl-Cysf.einyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys (4- C* G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, p Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 12.4 mg.
Amino Acid Analysis: Arg (3.9), Asp (1.0), Cha (1,0), Cys (1.2), Gly (2.1), lie (2.0), Phe (1.0).
FAB (M+H)+ at M/Z: 1602.
The 300 MHz NMR spectrum was found to be consistent with the proposed structure.
Example 12 Arginyl-Cyst.einyl-Cyclohexylalanyl- (D) Alanvl-Alanvl-Arqinvl-Tso] eucy 1 -Aspa rt.y 1 -A rai ny] -I soleucyl-P'nenvlalanvl-Arainvl-Cysteinyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-Arg(NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp(beta-cyclohexvl), Boc-Ile, Boc-Arg(N -Tos), Boc-Ala, 3oc-(D)Ala, Boc-Cha, Boc-Cys(4-MeBzl), Boc-Arg(NG-Tos), was 23 37 95 treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 40 mg.
Amino Acid Analysis: Ala (1.9), Arg (4.0), Asp (0.9), Cha (1.0), Cys (1.7), lie (2.0), Phe (1.0).
FAB (M+H)+ at M/Z: 1629.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 13 Arainy1-Cyste inyl-Tet rahydroisoauinolin-3-oy1-Glycyl-Glvcvl-Arainy 1-Isolency 1-Asparr.y 1-Arcinyl-Tsoleucyl-Phenyl a lanvl-Arainy 1-Cysf.einyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- G G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), 0 Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, n Boc-Gly, Boc-Tic, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 14.6 mg.
Amino Acid Analysis: Arg (4.0), Asp (1.1), Cys (1.7), Gly (1.9), lie (2.1), Phe (1.0).
FAB (M+H)+ at M/Z: 1607.
The 300 MHz "^H NMR spectrum was found to be consistent with the proposed structure. -2 9- 233795 Example 14 Arqinyl-Cvsteinyl-Phenylalanyl-Glynyl-Glycyl-Isoleucyl-ABpart-vl-Arqinvl-Isoleucvl-Phenvlalanvl-Arqinyl-Cysl-Pi nyl f.arboxamide Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- P G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Gly, Boc-Gly, Boc-Phe, Q Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 31 mg.
Amino Acid Analysis: Arg (3.0), Asp (1.0), Cys (1.8), Gly (1.9), lie (2.1), Phe (2.0).
FAB (M+H)+ at M/Z: 1439.
The 300 MHz "*"H NMR spectrum was found to be consistent with the proposed structure.
Example 15 Hist idyl-Cysteinyl-Cyclohexyla 1any1-Glycyl-Glycy1-Arqiny1-Isoleucy 1-Aspart.y 1-Arci ny 1-Isoleucy 1 -Phenylalanvl-Aroinyl-Cvst.einyl Carboxamide Cyclir Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenznydryamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- P P MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), 3oc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), Boc-His(N-Im-Tos), was 23 37 treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 13 mg.
Amino Acid Analysis: Arg (2.9), Asp (0.9), Cha (1.0), Cys (1.5), Gly (1.9), His (0.8), lie (2.0), Phe (1.0). FAB (M+H)+ at M/Z: 1583.
The 300 MHz ^H NMR was found to be consistent with the proposed structure.
Example 16 Arcrinyl-Cvsteinyl-Cvclohexylalanyl-GIycyl-GI vcvl-Arai nyl -Phenylalanyl-Aspartyl-Arainyl-Xsoleucyl—Phenylalanvl-Arainyl-Cysteinvl Carboxamide Cvnlir. Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- G G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), n Boc-Asp(beta-cyclohexyl), Boc-Phe, Boc-Arg(N -Tos), Boc-Gly, Q Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 25.1 mg.
Amino Acid Analysis: Arg (4.0), Asp (0.9), Cha (1.0), Cys (1.8), Gly (1.9), lie (1.1), Phe (2.1).
FAB (M+H)+ at M/Z: 1635.
The 300 MHz ^H NMR spectrum was found to be consistent with the proposed structure. 233795 Example 17 Cvsteinyl-Cvclohexylalanyl-Glycyl-Glycyl-Arginyl-Tsoleucy1-Aspartvl-Arginvl-Isoleucvl-Phenylalanvl-Agginvl-Cvsteinvl Carhoxamide Cyclic Disulfide Protected peptide resin (0.31 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys (4- C G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 2.3 mg.
Amino Acid Analysis: Arg (2.7), Asp (0.8), Cha (0.9), Cys (1.6), Gly (1.8), lie (1.9), Phe (1.1).
FAB (M+H)+ at M/Z: 1445.
The 300 MHz ^"H NMR spectrum was consistent with the proposed structure. axample IS Qrnithiny1-Cysteiny1-Cyclohexyla 1any1-Glycyl-Glycyl-Arginvl-Isoleucy1-Aspartyl-Arginy1-Tsoleucy1-Phenvlalanvl-Arainvi-Cvsteinyl Carboxamide Cyclic Disulfide Protected peptide resin (0.37 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- c c MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys, Boc-Orn(Cbz), was treated with HF 23 37 (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 20.0 mg.
Amino Acid Analysis: Arg (3.0), Asp (0.9), Cha (1.0), Cys (1.7), Gly (2.0), lie (2.1), Orn (1.0), Phe (1.0). FAB (M+H)+ at M/Z: 1559.
The 300 MHz "'"H NMR spectrum was found to be consistent with the proposed structure.
Example 19 AcetylArqinyl-Cysteinyl-Cyclohexylalanvl-Glvcv1-Glvcvl-Arginyl -Tsoleucy 1-Aspartv 1-Arainyl-T.soleucvl-Phenvialanyl-Arainyl—Cysteinyl Carboxamirie Cyclic Disulfide Protected peptide resin (0.30 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- c c MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, G Boc-Gly, Boc-Cha, Boc-Cys, Boc-Arg(N -Tos), was treated with HF and purified as described in Example 2. The N-terminal Arginyl residue was acetylated prior to purification with 0.3 H acetylimidazole in DMF (according to Step 6, Agenda A of Example 1). The title compound was obtained as a white powder, 2.3 mg.
Amino Acid Analysis: Arg (4.1), Asp (1.0), Cha (1.0), Cys (1.6), Gly (1.9), lie (2.0), Phe (1.1).
FAB (M+H)+ at M/Z: 1645. 1 The 300 MHz H NMR spectrum was found to be consistent with the proposed structure. 233795 Example 20 Cir.rullinYl-Cysr.einyl-Cvclohexvlalanyl-Glvcyl-GlycvI-Agqinyl-T so 3 eucyl-Asoa rt.yl - Arcriny 1-Tso leucy 1-Phenyla lany 1—Agqinyl-Cvsr einy1 Cagboxanride Cyclic Disulfide Protected peptide resin (0.42 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- G G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), Boc-Cit, was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 24.9 mg.
Amino Acid Analysis: Arg (3.0), Asp (1.0), Cys (1.2), Gly (1.6), lie (1.6), Phe (1.2).
FAB (M+H)+ at M/Z: 1602.
The 300 MHz 1H NMR spectrum was found to be consistent with the proposed structure.
Example 21 Arainyl-Cystp-i nyl-Cyclohexylalanyl-Glycvl-Glvcvl-Arqinvl-Isoleucvl-Aspagty1-Arqiny1-Isoleucyl-Phenvlalanvl-Cvsteinv1 Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- Q MeBzl), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Boc-Asp(beta- £ cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc- Q Cha, Boc—Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF 23 3 7 (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 20.6 mg.
Amino Acid Analysis: Arg (3.0), Asp (1.0), Cha (1.0), Cys (1.7), Gly (1.9), lie (2.0), Phe (1.1).
FAB (M+H)+ at M/Z: 1447.
The 300 MH 1H NMR spectrum was found to be consistent with the proposed structure.
Example 22 Arginy1-Cyste1 ny 1-3 . 5-Di iodotvros iny 1-Glycyl-Glvcy l-Arcrinvl-Isoleucvl-Aspart yl-Arainyl-Isoleucy 1-Phenvlalany1-Arainyl-Cysteinyl Carboxamide Cyclic Disulfide Protected peptide (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys (4- G G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), G Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, £ Boc-Gly, Boc-Tyr(2-BrCbz), Boc-Cys(4-MeBl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. Iodination of the tyrosine occurred during the oxidation (i.e. cyclization) of the peptide with 0.01 N iodine solution as described in Example 2. The title compound was obtained as a white powder, 25 mg.
Amino Acid Analysis: Arg (4.0), Asp (1.1), Cys (1.4), Gly (1.9), lie (2.0), Phe (1.0), Tyr (1.0).
FAB (M+H)+ at M/Z: 1865.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure. 23 37 95 Ssamplft ?3 Arginy1-Cysteiny1-Cvclohexylalany1-G1vcyl-Glycyl-ArginyI-Isoleucyl-Aspartyl-Arainy1-Tsoleucy l-Arainyl-Cysteinyl Carboxamirie Cvcl i r Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- G G MeBzl), Boc-Arg(N -Tos), Boc-Ile, Boc-Arg(N -Tos), Boc- G Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc- £ Gly, Boc-Cha, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) as described in Example 2. The title compound was obtained as a white powder, 28 mg.
Amino Acid Analysis: Arg (4.2), Asp (1.1), Cha (1.0), Cys (1.6), Gly (2.0), lie (1.8).
FA3 (M+H)+ at M/Z: 1455.
The 300 MHz "'"H NMR spectrum was found to be consistent with the proposed structure.
Example 24 Arginy1-Cysteinvl-Cyclohexvlalanyl-Glycvl-Glycy1-f cyclo(Lysinyl-Isoleucyl-Aspartyl)1-Arainyl-Isoleucvl- Phenylalanyl-Arainyl-Cyst:inyl Carboxamide Cyclic Disulfide Protected peptide resin (0.43 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- c c* MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), 3oc-Lys-Ile-Asp, Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), 233795 Q Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The side chain amino group of lysine in the tripeptide Lys-Ile-Asp was cyclized with the side chain carboxylic acid group of aspartic acid by standard DPPA coupling techniques. The tripeptide was incorporated during the solid phase synthesis as the Boc-protected cyclized tripeptide acid dissolved in N-methyl pyrrolidone. The title compound was obtained as a white powder, 2.8 mg.
Amino Acid Analysis: Arg (3.2), Asp (0.8), Cha (1.0), Cys (0.9), Gly (2.0), lie (2.0), Lys (0.9), Phe (1.1). FAB (M+H)+ at M/Z: 1556.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 2 5 Arginy 1-Cyst.elnyl -Cyclohexy la lany 1-Glycyl-Glycy 1-Arainy 1-Isoleucyl-Aspartyl-Arginyl-Isoleucyl-Glycy1-Alanyl-Cysteiny1 Carboxarnide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- Q MeBzl), Boc-Ala, Boc-Gly, Boc-Ile, Boc-Arg(N -Tos), Boc- 0 Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc- Q Gly, Boc-Cha, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 15 mg.
Amino Acid Analysis: Ala (1.0), Arg (3.0), Asp (1.0), Cha (1.0), Cys (1.8), Gly (3.0), lie (2.2).
FAB (M+H)+ at M/Z: 1426. 23 3795 The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 26 Arcrinvl -Cystei ny1-Cycl ohexy la I anvl -G1 ycvl-Glycy 1 -Arainyl-Isolsucy1- (D)Aspartyl-Arainyl-Isoleucy]-Phenylalanvl-Arainvl-Cysteinyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added in the following order: Boc-Cys(4-MeBzl) , Boc-Arg(NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-(D)-Asp(beta-Bzl), Boc-Ile, Boc-Arg(NG-Tos), Boc-Gly, Boc-Gly, Q Boc-Cha, Boc-Cys(4-MeBzl) , Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 15.3 mg.
Amino Acid Analysis: Arg (3.7), Asp (1.1), Cha (0.9), Cys (1.4), Gly (2.2), lie (2.2), Phe (0.9).
FAB (M+H)+ at M/Z: 1602.
The 300 MHz 1H NMR spectrum was found to be consistent with the proposed structure.
Example 27 (D)Arainy 1-Cyste iny 1-Cyclohexyla lany 1-Glvcvl-Givevl-Arcfiny 1-Isoleucy1-Asparty1-Arainyl-Isoleucyl-Phenvialanv1-ArQinvl-Cysteinyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- 23 3795 G Q MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Q Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), Boc-(D)Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 18.7 mg.
Amino Acid Analysis: Arg (4.0), Asp (0.9), Cha (1.0), Cys (1.3), Gly (2.1), lie (2.2), Phe (0.9) FAB (M+H)+ at M/Z: 1601.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 28 Arainyl -Cystsi ny'i -Cyclohexylalycine-Glycyl-Glvcyl-Arainyl-Isoleucy1-Asoartyl-Arainyl-Isoleucyl-Phenylalanvl-Arqinvl-Cvst:einvl Carboxamide Cyclic. Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- C* G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Chg, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 30 mg.
Amino Acid Analysis: Arg (4.2), Asp (0.8), Cys (1.9), Gly (1.8), lie (2.1), Phe (1.0).
FAB (M+H)+ at M/z: 1588. i The 300 MHz ~H NMR spectrum was found to be consistent with the proposed structure. 23 37 95 Example 2 9 Arcrlnvl—CystIny 1-Cyclohexy la lany 1-Glycyl-Glycy 1-Arciny 1 -T so leucy 1-Aspart yl-Aroir. y 1-Alany 1-Pheny la la nyl-Arainyl -Cvsr.einyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g) , prepared, from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys (4-MeBzl), Boc- P G Arg(N -Tos), Boc-Phe, Boc-Ala, Boc-Arg(N -Tos), Boc-Asp(beta- Q cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc- Q Cha, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 30 mg.
Amino Acid Analysis: Ala (1.0), Arg (4.2), Asp (0.9), Cha (1.0), Cys (1.3), Gly (1.8), lie (1.2), Phe (1.0). FAB (M+H)+ at M/Z: 1560.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 30 Arginyl-Cysteinyl- (D)Cyclohexylalanyl-Glycvl-Glvcvl-Arainy1-Isoleucyl-Aspartyl-Arainyl-Isoleucyl-?henylalanvl-Arainyl-Cyst.einyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- P P MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Q Boc-Gly, Boc-(D)Cha, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was 23 37 treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 8 mg.
Amino Acid Analysis: Arg (3.7), Asp (1.1), Cha (1.1), Cys (0.7), Gly (2.1), lie (2.0), Phe (1.0) FAB (M+H)+ at M/Z: 1602.
The 300 ^H NMR spectrum was found to be consistent with the proposed structure.
Example 31 Arcrinvl—CvstPj nvl-Cvclohexvl a 1 anv l-Glvcvl—Glvcvl —Arginvl -Isoleucvl-Alanvl-Arginvl-Isoleiarvl -Alanvl-Arainvl-Cvsteinvl Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from Boc-Cys(4-MeBzl)-O-Merrifield resin and the amino acids added sequentially in the following order: Boc- G G Arg(N -Tos), Boc-Ala, Boc-Ile, Boc-Arg(N -Tos), Boc-Ala, Boc- r* lie, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4- Q MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 22.4 mg.
Amino Acid Analysis: Ala (1.7), Arg (4.3), Cha (1.0), Cys (1.7), Gly (1.9), lie (2.0).
FAB (M+H)+ at M/Z: 1482.
The 300 MHz ^H NMR was found to be consistent with the proposed structure. 233795 Example 32 Mercapt.opropionyl-Cyclohexylalanvl-Glvcyl-Glycyl-Arginyl-Tsolenoyl-Aspartvl-Arainy 1-Tsoleucy 1-Phenyla lany 1-Arairty 1-r.ysteinyl Carboxamide Cyclic Disulfide Protected peptide resin (0.30 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- P c MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Mpa(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 27.0 mg.
Amino Acid Analysis: Arg (2.9), Asp (1.0), Cha (1.0), Cys (1.2), Gly (2.1), lie (2.0), Phe (1.0).
FAB (M+H)+ at M/Z: 1430.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 33 ■Arcrinyl-Cyst.einyl-Cyclohexy ialany 1-Glvcyl-Glvcvl- (D) Arainvl-Isoleucyl-Aspartyl-Arainyl-Tsoleucy1-Phenylalanvl-Arqinvl- Cysr.einy 1 Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from Boc-Cys(4-MeBzl)-O-Merrifield resin and the amino acids added sequentially in the following order: Boc-Arg (NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp(beta- p cyclohexyl), Boc-Ile, Boc-(D)Arg(N -Tos), Boc-Gly, Boc-Gly, p Boc-Cha, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with \ 233795 HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 40 mg.
Amino Acid Analysis: Arg (4.0), Asp (1.0), Cys (1.8), Gly (2.0), lie (2.1), Phe (1.0).
FAB (M+H)+ at M/Z: 1602.
The 300 MHz *H NMR spectrum was found to be consistent with the proposed structure.
Example 34 Arcrinyl-Cysteinyl-Per-Hydroindanecarbonyl-Glycvl-Glvcyl-Arginyl-Isoleucyl-Aspartyl-Arainyl-Isoleucvl-Phenvlalanvl-Aroinyl—Cy-steinvl Cyclic Disulfide Protected peptide resin (0.97 g), prepared (as described in Example 1) from Boc-Cys(4-MeBzl)-O-Merrifield resin and the amino acids added sequentially in the following order: Boc- p G Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Boc-Asp(beta- Q cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc- p Pic, Boc-Cys(4-MeBzl), Boc-Arg(N -Tos), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 81 mg.
Amino Acid Analysis: Arg (3.6), Asp (1.0), Cys (1.5), Gly (1.9), lie (2.3), Phe (1.2).
FAB (M+H)+ at M/Z: 1614.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure. 233795 Example 35 Seryl-Seryl -Cvsf.el nv I-Phenv lalanvl-Gl vcy 1-G1 ycyl -ArcH nyl -Tsoleucy 1-Asparty 1-Aroiny 1 -I soleucvl-Pheny la lany 1-Arginy1- rvsr.sinvl Cyclic Disulfide Protected peptide resin (0.79 g), prepared (as described in Example 1) from Boc-Cys(4-MeBzl)-O-Merrifield resin and the amino acids added sequentially in the following order: Boc- G G Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Boc-Asp (beta- Q cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Phe, Boc-Cys(4-MeBzl), Boc-Ser(Bzl), Boc-Ser(Bzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 70 mg.
Amino Acid Analysis: Arg (2.7), Asp (1.0), Cys (1.8), Gly (2.0), lie (2.0), Phe (1.9), Ser (1.8).
FAB (M+H)+ at M/Z: 1615.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 36 Cysteinvl-Cyclohexylalany1-Glycy1-Glycy1-Arginy1-Tsoleucvl-(D) Aspartvl -Arginy 1-1 sol eucyl -Phenvla 1 anvl-Arcriny 1 -Cystelnvl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- p g MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Boc-(D)Asp(beta-Bzl), Boc-Ile, Boc-Arg(NG-Tos), Boc-Gly, Boc- \ 233795 Gly, Boc-Cha, Boc-Cys(4-MeBzl) , was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 37.6 mg.
Amino Acid Analysis: Arg (3.1), Asp (1.0), Cha (0.9), Cys (1.7), Gly (1.8), lie (2.1), Phe (0.9).
FAB (M+H)+ at M/Z: 1445.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 37 Cysteinyl-Cyclohexylalanyl-Glycvl-niycvl-Arainvl-Isoleucvl-ftspartyl-ftrginyl-Alanyl-Phenylalanyl-Arginyl-Cysteinyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- G G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ala, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 30.7 mg.
Amino Acid Analysis: Ala (1.0), Arg (3.1), Asp (1.0), Cha (0.9), Cys (1.5), Gly (1.8), lie (1.1), Phe (1.0). FAB (M+H)+ at M/Z: 1403.
The 300 MHz "^H NMR spectrum was found to be consistent with the proposed structure.
Examole 38 23 3 7 Cysteiny1-Cyclohexvlalany1-Glycyl-Glycyl-Arainyl-Isoleucy1 Asparty1-Alanyl-Isoleucy1-Phenylalanyl-Arainyl-Cysteinyl Carboxamidg Cyclic Pi sulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- Q MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Ala, Boc- Q Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 16.0 mg.
Amino Acid Analysis: Ala (1.0), Arg (2.0), Asp (1.1), Cys (1.4), Gly (1.9), lie (2.0), Phe (1.0).
FAB (M+H)+ at M/Z: 1360.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 3 9 Mercaptopropiony1-Cyclohexylalanv1-G1vcv1-G1vcvl-ArainvI-Tsoleucy1-beta-Asparty1-Arainyl-Tsoleucy1-Phenvialanvl-Arainyl-Cysteinyl Carboxamirie Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- C G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-Ile, Boc-Arg(N -Tos), Q Boc-Asp(alpha-Bzl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Mpa(4-MeBzl), was treated with HF (liquid) and 23 37 9 5 purified as described in Example 2. The title compound was obtained as a white powder, 50.0 mg.
Amino Acid Analysis: Arg (3.1), Asp (1.0), Cha (0.8), Cys (0.5), Gly (1.9), lie (1.9), Phe (1.0).
FAB (M+H)+ at M/Z: 1430.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure.
Example 40 r.y.st.einyl—Cyrlohexvlal anyl-Gl ycvl-Glvcvl-Arainvl-Isnlencvl-Aspartyl-Arginyl-fD)Isoleucyl-Phenylalanyl-Arqinyl-Cysteinvl Carboxamnde Cyclic Pisulfide Protected peptide resin (0.45 g) , prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4- G G MeBzl), Boc-Arg(N -Tos), Boc-Phe, Boc-(D)lie, Boc-Arg(N -Tos), Q Boc-Asp(beta-cyclohexyl), Boc-Ile, Boc-Arg(N -Tos), Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 28.0 mg.
Amino Acid Analysis: Arg (3.2), Asp (1.0), Cha (1.0), Cys (1.8), Gly (2.1), lie (1.8), Phe (1.1).
FAB (M+H)+ at M/Z: 1445.
The 300 MHz ^"H NMR spectrum was found to be consistent with the proposed structure. 23 3795 Example 41 Cysteinyl-Cyclohexylalanyl -C51 ycvl-Glycyl-Arqinyl-Norva 1 yl -Asoarf.v 1-Arainvl-Norvalv 1-Phen via lany 1 -Arqinvl-Cvste inyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-Arg(N^-Tos), Boc-Phe, Boc-Nva, Boc-Arg(N^-Tos) , Boc-Asp ((3-Bzl) , Boc-Nva, Boc-Arg (N^-Tos) , Boc-Gly, Boc-Gly, Boc-Cha, Boc-Cys(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 23 mg.
Amino Acid Analysis: Arg (3.1), Asp (0.9), Cys (1.7), Gly (2.0), Nva (2.0), Phe (1.0) plus Cha.
FAB (M+H)+ at M/Z: 1417.
The 500 MHz ^H NMR spectrum was found to be consistent with the proposed structure.
Example 42 Cvst.ei nvl- (D) PhfrnylqlvcvI-Glycvl-Glvcvl-Arcinyl-ISQleucvl-Aspartyl-Arginyl-Xsoleucyl-Phenylalanyl-Arqinvl-Cysteiny1 Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-Arg(NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp(P~Bzl), Boc-Ile, Boc-Arg(N^-tos), Boc-Gly, Boc-Gly, Boc-(D)Phg, Boc-Cys(4-MeBzl), was treated with HF (liquid) and 23 37 95 purified as described in Example 2. The title compound was obtained as a white powder, 25 mg.
Amino Acid Analysis: Arg (3.0), Asp (1.0), Cys (1.8), Gly (2.0), lie (2.0), Phe (1.0).
FAB (M+H)+ at M/Z: 1425.
The 500 MHz ^-H NMR spectrum was found to be consistent for the proposed structure.
Example 43 3-Mercaptopropionvl-Cyclohexvlalanvl-Glvcyl-Glvcvl-Arqinvl-Isoleucyl-Aspartyl-Arginy1-T.soleucy1-Phenylalanv1-(D)Arginy1-Pystei nvl P.a rhovami rie Cvclir Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-(D)Arg(NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp(P~tert-butyl.) , Boc-Ile, Boc-Arg(NG-Tos), Boc-Gly, Boc- Gly, Boc-Cha, Mpa(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 19.1 mg.
Amino Acid Analysis: Arg (2.9), Asp (1.0), Cys (0.5),. Gly (2.0), lie (2.1), Phe (1.0) plus Cha, Mpa.
FAB (M+H)+ at M/Z: 1431.
The 500 MHz 1H NMR spectrum was found to be consistent for the proposed structure. 233795 cvamplff 44 3-Mercapr opropionyI-Cyr:l ohexvlalanvl-Glvcy1-Glvcvl-Arqinvl-Isoleucyl-Aspart. yl-Arcri n.y 1 - Tsoleucy1-Phenylalany1-Arqinyl-(D) Cysr.einyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-(D)Cys (4-MeBzl), Boc-Arg(NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp(3-benzyl) , Boc-Ile, Boc-Arg(NG-Tos), Boc-Gly, Boc-Gly, Boc-Cha, Mpa(4-MeBzl) , was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 12.0 mg.
Amino Acid Analysis: Arg (3.0), Asp (1.0), Cys (0.5), Gly (1.7), lie (2.0), Phe (1.0) plus Cha, Mpa.
FAB (M+H)+ at M/Z: 1430.
The 500 MHz ^H NMR spectrum was found to be consistent for the proposed structure.
Example 4 5 3-Mercaptopropionyl-rycTohexvlalanvl-(D)Alanvl-Arqinvl-Arainvl-Tsoleurvl-Asoartyl-Arainvl-Tsoleucvl-Phenvlalanvl-Arginyl-Cysteinyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-Arg(NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp (|3-tert-butyl) , Boc-Ile, Boc-Arg (NG-Tos) , Boc-Arg (NG- Tos), Boc-(D)Ala, Boc-Cha, Mpa(4-MeBzl), was treated with HF 233795 (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 51 mg.
Amino Acid Analysis: Ala (0.9), Arg (4.2), Asp (0.9), Cys (0.4), lie (2.0), Phe (1.0) plus Cha, Mpa.
FAB (M+H)+ at M/Z: 1545.
The 500 MHz 1-H NMR spectrum was found to be consistent for the proposed structure.
Example 4 6 CysteinYl-Phenylalanyl-Glycvl-Glvcyl-Arqinvl-Arqinvl-Leucvl-Asparty1-Arainyl-Tsoleucy1-Leucyl-Arainy1-Cysteinvl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-Arg(NG-Tos), Boc-Leu, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp (P~Bzl), Boc-Leu, Boc-Arg(NG-Tos), Boc-Arg(NG-Tos), Boc-Gly, Boc-Gly, Boc-Phe, Boc-Cys (4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 54 mg.
Amino Acid Analysis: Arg (4.2), Asp (0.9), Cys (1.8), Gly (0.9), lie (1.0), Leu (2.1), Phe (1.0).
FAB at M/Z: 1505.
The 500 MHz ^-H NMR spectrum was found to be consistent for the proposed structure. 233795 Example 47 3-Mprcaptopropionvl-Cvc lohexylalariy 1-Glycvl-Glvcy 1-Arainyl-T so 1 <=>ucy 1-Glutamvl-Ara iny 1-Tsoleucy 1-Phenvlalanyl-Arainyl-Cysteinyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-Arg(NG-Tos) , Boc-Phe, Boc-Ile, Boc-Arg (NG-Tos), Boc-Glu(Bzl), Boc-Ile, Boc-Arg(NG-Tos), Boc-Gly, Boc-Gly, Boc-Cha, Mpa(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 140 mg.
Amino Acid Analysis: Arg (3.1), Cys (0.4), Glu (1.0), Gly (2.1), lie (2.0), Phe (1.0) plus Cha, Mpa.
FAB (M+H)+ at M/Z: 1445.
The 500 MHz -^-H NMR spectrum was found to be consistent for the proposed structure Example 4 8 3-Mercaptopropionyl-Cyclohexylalanyl-Gl ycyl-Glvcyl-fD)Arainvl-Tsoleucyl-Aspartvl-Arainyl-Tsoleucy1-Phenvialanvl-Arainvl-Cysteinvl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-Arg(NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp (|3-Bzl) , Boc-Ile, Boc-(D)Arg(NG-Tos), Boc-Gly, Boc-Gly, Boc-Cha, Mpa(4-MeBzl), was treated with HF (liquid) and \ 23 37 95 purified as described in Example 2. The title compound was obtained as a white powder, 47 mg.
Amino Acid Analysis: Arg (3.0), Asp (1.0), Cys (0.5), Gly (1.6), lie (1.6), Phe (1.0) plus Cha, Mpa.
FAB (M+H)+ at M/Z: 1430.
The 500 MHz ^H NMR spectrum was found to be consistent for the proposed structure. f.y amnio 49 3-Mercaptopropionyl-CyclohexyIalap.yl-c;iycvl-Glvcyl-Arqlnvl-Isoleucyl—Aspartyl-Arainyl-Isoleucy1—(D)Phenvlalanvl-Arainvl-Cysteinyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-Arg(NG-Tos), Boc-(D)Phe, Boc-Ile, Boc-Arg(N^-Tos), Boc-Asp ({3-tert-butyl) , Boc-Ile, Boc-Arg (NG-Tos), Boc-Gly, Boc- Gly, Boc-Cha, Mpa(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 12.0 mg.
Amino Acid Analysis: Arg (3.1), Asp (1.0), Cys (0.6), Gly (2.0), lie (2.0), Phe (1.1) plus Cha, Mpa.
FAB (M+H)+ at M/Z: 1431.
The 500 MHz ^H NMR spectrum was found to be consistent for the proposed structure. 233795 Example 50 6-A.minohexanoyl-Cysteinvl-Cyclohexylalanyl-fD)Alanyl-rm R1 anvl—Arcrinyl —Isoleucy 1-AspartyI-Arainy 1 -Tsoleucy! -Phenyls 1 anvl-Arai nvl -Cvst. einv 1 Carboxamide Cyclic Disulfide Protected peptide resin (0.50 a), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-Arg(NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp (|J-Bzl) , Boc-Ile, Boc-Arg (NG-Tos), Boc-(D) Ala, Boc- (D)Ala, Boc-Cha, Boc-Cys(4-MeBzl), Boc-Aha, was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 39 mg.
Amino Acid Analysis: Ala (1.9), Arg (3.2), Asp (1.0), Cys (1.6), lie (2.0), Phe (1.0) plus Cha.
FAB (M+H)+ at M/Z: 1587.
The 500 MHz ^-H NMR spectrum was found to be consistent for the proposed structure Example Si. 3—Ntercaptonron-i onyl-Cvclohexvl a 1 any! -G1 ycy 1-Glycy 1-Arainyl-Tsol encyl-Histidinvl-Aroinvl-Tsoleucvl-Phenyl a 1 anvl-Arainvl-Cvsteinvl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-Arg(NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-His(Nim-Tos), Boc-Ile, Boc-Arg(NG-Tos), Boc-Gly, Boc-Gly, Boc-Cha, Mpa(4-MeBzl), was treated with HF (liquid) and 23 37 95 purified as described in Example 2. The title compound was obtained as a white powder, 10.0 mg.
Amino Acid Analysis: Arg (3.2), Cys (0.5), Gly (2.5), His (0.9), lie (1.9), Phe (1.0) plus Cha, Mpa.
FAB (M+H)+ at M/Z: 1453.
The 500 MHz *H NMR spectrum was found to be consistent for the proposed structure.
Example 5 2 3-Mercaptopropionyl-Phenylalanyl-Glycvl-Glvcyl—Arcrinvl-Isoleucvl-Aspart yl -Arainy 1-Isoleucyl-Pheny la lany1-Arainyl-Cvsteinyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-Cys(4-MeBzl), Boc-Arg(NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp(P~Bzl), Boc-Ile, Boc-Arg(NG-Tos), Boc-Gly, Boc-Gly, Boc-Phe, Mpa(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 25 mg.
Amino Acid Analysis: Arg (3.0), Asp (0.9) Cys (0.5), Gly (2.0), lie (2.0), Phe (2.0) plus Mpa.
FAB (M+H)+ at M/Z: 1424.
The 500 MHz 1-H NMR spectrum was found to be consistent for the proposed structure. 3 7 Fxample 53 3-Mercaptopropinnyl-Cyclohexylalanyl-(D)Alanvl—Alanyl—Arainyl— Isolencyl-Aspari-yl-Arainyl-Isoleucvl-Phenvlalanvl-Arqinyl-(mCysi-ginyl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g) , prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-(D)Cys(4-MeBzl), Boc-Arg(NG-Tos), Boc-Phe, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp(b-tert-butyl), Boc-Ile, Boc-Arg(NG-Tos), Boc-Ala, Boc-(D)Ala, Boc-Cha, Mpa(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 33.1 mg.
Amino Acid Analysis: Ala (1.6), Arg (3.2), Asp (1.0), Cys (0.5), lie (2.0), Phe (1.0) plus Cha, Mpa.
FAB (M+H)+ at M/Z: 1459.
The 500 MHz *H NMR spectrum was found to be consistent for the proposed structure.
Example 54 3-Mercaptopropiony1-Cvclohexvlalanvl-(D)Alanvl-Alanvl-Arainvl-Isoleucyl-Aspartyl-Arainvl-Isoleucvl-N^-f 3~(l-Phenvl-2-aminopropionylHArainyl-(D)Cvsteinvl Carboxamide Cyclic Disulfide Protected peptide resin (0.50 g), prepared (as described in Example 1) from p-methylbenzhydrylamine resin and the amino acids added sequentially in the following order: Boc-(D)Cys(4-MeBzl), Boc-Phe-Arg(NG-Tos) reduced amide, Boc-Ile, Boc-Arg(NG-Tos), Boc-Asp(0-tert-butyl), Boc-Ile, Boc-Arg(NG-Tos), 23 37 9 Boc-Ala, Boc-(D)Ala, Boc-Cha, Mpa(4-MeBzl), was treated with HF (liquid) and purified as described in Example 2. The title compound was obtained as a white powder, 7.4 mg.
Amino Acid Analysis: Ala (2.0), Arg(2.2), Asp (0.8), Cys (0.5), lie (1.6) plus Cha, Mpa.
FAB (M+H)+ at M/Z: 1445.
The 5 00 MHz NMR spectrum was found to be consistent for the proposed structure.
The representative compounds of the invention described in the above examples are summarized in Table 1, below: Example 55 Table 1 ANP Agonist Sequences Example No Sequence 6 7 2 3 4 8 11 12 13 9 R-C-Cha-(D)A-G-G-R-L-D-R-I-F-R-C-Amide S-S-C-Cha-G-G-R-I-D-R-I-F-R-C S-S-C-Cha-G-G-R-I-D-R-I-Cha-R-C R-C-F-G-G-R-I-D-R-I-F-R-C-Amide R-C-(D)A-Cha-G-G-R-L-D-R-I-F-R-C-Amide R-C-Cha-G-G-R-I-D-R-I-F-R-C S-S-C-Cha-G-G-(D)R-I-D-R-I-F-R-C C-Cha-G-G-R-I-D-R-I-F-R-C C-R-Cha-G-G-R-I-D-R-I-F-R-C R-C-Cha-G-G-R-I-D-R-I-F-R-C-Amide R-C-Cha-(D)A-A-R-I-D-R-I-F-R-C-Amide R-C-Tic-G-G-R-I-D-R-I-F-R-C-Amide 14 16 17 18 19 21 22 23 24 26 27 28 29 31 32 33 34 36 37 38 39 40 41 42 43 44 45 46 23 3795 R-C-F-G-G-I-D-R-I-F-R-C-Amide H-C-Cha-G-G-R-I-D-R-I-F-R-C-Amide R-C-Cha-G-G-R-F-D-R-I-F-R-C-Amide C-Cha-G-G-R-I-D-R-I-F-R-C-Amide Orn-C-Cha-G-G-R-I-D-R-I-F-R-C-Amide AcetylR-C-Cha-G-G-R-I-D-R-I-F-R-C-Amide Cit-C-Cha-G-G-R-I-D-R-I-F-R-C-Amide R-C-Cha-G-G-R-I-D-R-I-F-C-Amide R-C-3,5-l2Y-G-G-R-I-D-R-I-F-R-C-Amide R-C-Cha-G-G-R-I-D-R-I-R-C-Amide R-C-Cha-G-G- cyclo (K-I-D) -R-I-F-R-C-Amide R-C-Cha-G-G-R-I-D-R-I-G-A-C-Amide R-C-Cha-G-G-R-I-(D)D-R-I-F-R-C-Amide (D)R-C-Cha-G-G-R-I-D-R-I-F-R-C-Amide R-C-Chg-G-G-R-I-D-R-I-F-R-C-Amide R-C-Cha-G-G-R-I-D-R-A-F-R-C-Amide R-C- (D)Cha-G-G-R-1-D-R-1-F-R-C-Amide R-C-Cha-G-G-R-I-A-R-I-A-R-C Mpa-Cha-G-G-R-I-D-R-I-F-R-C-Amide R-C-Cha-G-G-(D)R-I-D-R-I-F-R-C R-C-Pic-G-G-R-I-D-R-I-F-R-C S-S-C-F-G-G-R-I-D-R-I-F-R-C C-Cha-G-G-R-I-(D)D-R-I-F-R-C-Amide C-Cha-G-G-R-I-D-R-A-F-R-C-Amide C-Cha-G-G-R-I-D-A-I-F-R-C-Amide Mpa-Cha-G-G-R-I-betaD-R-I-F-R-C-Amide C-Cha-G-G-R-I-D-R-(D)I-F-R-C-Amide C-Cha-G-G-R-Nva-D-R-Nva-F-R-C-Amide C-(D)F-G-G-R-I-D-R-I-F-R-C-Amide Mpa-Cha-G-G-R-1-D-R-1-F- (D)R-C-Amide Mpa-Cha-G-G-R-I-D-R-I-F-R-(D)C-Amide Mpa-Cha-(D)A-R-R-I-D-R-I-F-R-C-Amide C-F-G-G-R- R-L-D-R-I-L-R-C-Amide 23 37 47 Mpa' -Cha-G-G-R-I-E-R-I-F-R-C-Amide 48 Mpa' -Cha-G-G-(D)R-I-D-R-I-F-R-C-Amide 49 Mpa' -Cha-G-G-R-I-D-R-I-(D) F-R-C-Amide 50 Aha- -C-Cha-(D)A-(D)A-R-I-D-R-I-F-R-C-Amide 51 Mpa- -Cha-G-G-R-I-H-R-I-F-R-C-Amide 52 Mpa- -F-G-G-R-I-D-R-I-F-R-C-Amide 53 Mpa- -Cha-(D)A-A-R-I-D-R-I-F-R-(D)C-Amide 54 Mpa- -Cha- (D) A-A-R-I-D-R-I- [F^R] - (D) C-Amide Other peptides of the invention which can be synthesized according to the methods of Examples 1 and 2 include the following: Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Cys-Phe-Gly-Gly-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Cys-Phe-Gly-Gly-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; Cys-Phe-Gly-Gly-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-Gly-Gly-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-Gly-Gly-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-Gly-Gly-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-Gly-Gly- (D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-Gly-Gly-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-Gly-Gly-Ile-Leu-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-Gly-Gly-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-Cys-Gly-Gly-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-Gly-Gly-Ile-Asp-Arg-Ile-Phe-Arg-Cys; hCys-Phe-(D)Ala-Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg—Cys; 233795 hCys-Phe-(D)Ala-Ala-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; hCys-Phe-(D)Ala-Ala-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; hCys-Phe-(D)Ala-Ala-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; hCys-Phe-(D)Ala-Ala-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-(D)Ala-Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-(D)Ala-Ala-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-(D)Ala-Ala-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-(D)Ala-Ala-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Arg-Cys-Phe-(D)Ala-Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-(D)Ala-Ala-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-(D)Ala-Ala-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-(D)Ala-Ala-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-(D)Ala-Ala-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Cys-Phe-Gly-Gly-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-Gly-Gly-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-Glv-Gly-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-Gly-Gly-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-Gly-Gly-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-Cys-Gly-Gly-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-Gly-Gly-Ile-Asp-Arg-Ile-Phe-Arg-Cys; hCys-Phe-(D)Ala—Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; hCys-Phe-(D)Ala-Ala-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; hCys-Phe-(D)Ala-Ala-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; hCys-Phe-(D)Ala-Ala-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; hCys-Phe-(D)Ala-Ala-lie-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-(D)Ala-Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-(D)Ala-Ala-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-(D)Ala-Ala-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-(D)Ala-Ala-Ile-Asp-Arg-Ile-Phe-Arg-Cys; 23 3795 Arg-Cys-Phe-(D)Ala-Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-(D)Ala-Ala-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-(D)Ala-Ala-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Phe-(D)Ala-Ala-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-(D)Ala-Ala-Ile-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-(D)Ala-Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-(D)Ala-Ala-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; His-Cys-Phe-(D)Ala-Ala-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys; and His-Cys-Phe-(D)Ala-Ala-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys.
Example 5 6 Preparation of Plasma Membranes Adrenal cell membranes were prepared for use in binding assays as follows: Weighed frozen mature rabbit adrenals (Pel-Freez) were pulverized in a liquid-nitrogen-cooled mortar. The plasma membrane powder was transferred to assay buffer (50mM HEPES (4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid), 100 mM NaCl, 5 mM EGTA (ethylene glycol bis(.beta.-aminoethyl ether)-N,N,N',N'-tetraacetic acid), 1 mM PMSF (phenyl methylsulfonyl fluoride), 0.01% Brij-35 detergent, 0.01% Bovine Serum Albumin, 0.1% Bacitracin, 5 mM MnCl2, 1 micromolar leupeptin, 1 micromolar phosphoramidon, pH 7.4) and homogenized in a Polytron three times at 10 seconds each time. The homogenate was centrifuged at 20,000 g for 15 min at 4°C. The supernatant was decanted. The pellet was resuspended in assay buffer and homogenized with the Polytron (2 X 10 sec) and again centrifuged at 20,000 g at 4°C. The supernatant decantation and pellet resuspension were repeated two additional times. The final homogenate was diluted to a concentration of 0.16 mg/mL (wet tissue weight) in assay buffer and stored at -80°C until used. 233795 Example 5 7 ANP Receptor Binding Assay The in vitro receptor binding of the compounds of the present invention was studied as follows: 0.53 mg rabbit 125 adrenal plasma membranes were incubated with 2 6.1 pM I-rat ANP and various concentrations of competing analogs for 90 min at 4°C in a total volume of 0.2 mL of assay buffer. Bound 125 I-rat ANP was separated from free ligand by rapid filtration through 0.1% polyethylenimine-treated 240-1 glass-fiber filter strips (Cambridge Technology), followed by rapid washing with ice cold saline. The filters were counted for radioactivity in a LKB 1277 Gammamaster counter with 76% 125 counting efficiency. Triplicate determinations of bound I-rat ANP were used for data analysis. Binding data was analyzed by computer assisted non-linear regression analysis using the LIGAND program (Munson, P.J. and M. Rodbard, Analytical Biochemistry. 107, 220-239 (1980)) for determination of density of binding sites on the membrane and for determination of the competing analog's affinity for the binding sites. In the case of selective analogs only the low affinity binding values (pKi,) are reported. Table 2, below, which contains the ANP receptor binding data, demonstrates the affinity of the atrial peptide derivatives of the present invention for ANP binding receptor sites. 233795 Table 2 ANP receptor binding data * * * * * * Ex. No.
BKi Ex. No.
Ex. No. 2 6.34 .70 38 .44 3 6.94 21 6 .97 39 6.11 4 6.93 22 .88 40 6.84 6.06 23 6 .71 41 .94 6 6.22 24 7 .24 42 6. 90 7 6.34 .91 43 6.42 8 .66 26 6 .22 44 6.02 9 6.14 27 6 .75 45 6. 68 6. 60 28 6 .23 46 6.01 11 6.63 29 6 .63 47 6.37 12 6.69 6 .45 48 6.45 13 .61 31 6 .61 49 .19 14 .05 32 6 .74 50 6.75 6.73 33 6 .14 51 6.36 16 6.17 34 6 .32 52 6.05 17 6.56 6 .10 54 7.20' 18 6.20 36 .45 19 6.43 37 6 .73 if ic = Negative logarithm of ligand binding constant 23 3795 Example 58 In Vivo Testing The in vivo effect of the compounds of the present invention on blood pressure and sodium output were studied as follows: Male Sprague-Dawley rats (4-12 rats weighing 200-250 mg each) were anesthetized with inactin administered intraperotoneally at a dose of 100 mg/kg. The test compounds were infused intravenously in 0.1% bovine serum albumin (BSA) in saline solution at a rate of 1 mL per hour for 15 minutes at each dose level. For routine screening the doses administered were 0.1, 0.3, 1.0, 3.0, 10.0 and 30.0 jig/kg/min.
Blood pressure, urine volume output, sodium and potassium secretion were measured over a 15 minute period at each dose.
Test compounds were regarded as active if they produced either a three-fold increase in sodium excretion or a 5% decrease in blood pressure at the doses tested. The results for change in blood pressure and sodium output are shown in Table 3 and demonstrate the ability of the compounds of the present invention to modify vascular and renal funct ion.
Table 3 Effect on Blood Pressure and .Sodium Output Example Dose (fla/ka) A B. P . (%) JUL A Sodium* (N) 4 0 .100 0 .300 1.000 3.000 10.000 30.000 -0.20 8 0.11 8 3.11 8 -3.14 8 -7.25 8 -8.45 8 0.22 0.24 0.44 0.52 5 5 0.82 1.07 23 37 95 Example 6 7 Table 3 (conr.inug'l) Dose (Lta/ka) A B. P. (%) (N) A Sodium* (m 0.100 0.35 8 0.11 6 0.300 0.86 8 0.18 6 1.000 -0.7 6 8 0.29 6 3.000 -3.30 8 0.43 6 .000 -4.84 8 0.49 6 .000 -6.79 8 0.59 6 0.100 -0.95 0.300 -1.25 1.000 -3.65 3.000 -5.30 .000 -7.93 .000 -9.30 4 -0.07 4 4 -0.02 4 4 -0.13 4 4 0.04 4 4 0.04 4 4 0.02 4 0.100 -0.47 0.300 -1.20 1.000 -2.90 3.000 -7.32 .000 -8.88 .000 -7.08 6 0.10 6 6 0.14 6 6 0.36 6 6 0.57 .6 6 0.75 6 6 1.12 6 0.100 0.300 1.000 3.000 .000 .000 2.50 0.86 -0.8 9 -2.05 -4.55 -7.79 8 8 8 8 8 8 0.21 0.22 0.42 0. 60 0. 64 0.84 6 6 6 6 6 \ 233795 Table 3 (continued) Example Dose (Llq/kq) A B.P. (%) (N) A Sodium* (N) 9 0.100 -2.60 6 0.05 5 0.300 -3.47 6 0.05 5 1.000 -4.68 6 0.17 5 3.000 -6.90 6 0.34 5 10.000 -12.00 6 0.62 5 30.000 -16.88 6 0.82 5 0.100 -1.98 12 -0.05 8 0.300 -3.51 12 0.00 8 1.000 -4.60 12 0.06 8 3.000 -5.25 12 0.22 8 10.000 -7.42 12 0.38 8 30.000 -7.92 12 0.77 8 11 0.100 -1.49 12 -0.01 9 0.300 -2.27 12 0.06 9 1.000 -4.64 12 0.07 9 3.000 -7.64 12 0.28 9 10.000 -10.93 12 0.46 9 30.000 -12.42 12 0.85 8 12 0.100 -3.08 5 0.25 4 0.300 -4.22 5 0.55 4 1.000 -8.70 5 0.66 4 3.000 -12.46 5 0.91 4 10.000 -17.54 5 1.14 4 30.000 -24.98 5 1.09 4 233795 Table 3 (continued) Example Dose (fla/ka) A g,P. (%) (N) A Sodium* (N) 14 0.100 0 .300 1.000 3.000 .000 .000 -0.60 -8.10 -7 .07 -9.13 -9.20 -9.65 4 4 4 4 4 4 -0.03 -0.10 -0.13 0.01 0.14 0.18 4 4 4 4 4 4 0.100 0.300 1.000 3.000 .000 .000 -0.25 -3 .72 -8.60 -14 .17 -17.95 -18.90 -0.23 -0.20 0.15 0.78 0. 97 1.38 5 5 5 5 5 17 18 0.100 0.300 1.000 3.000 .000 .000 0.100 0.300 1.000 3.000 .000 .000 -0.42 -1.22 -2.49 -4.70 -8. 63 -15.83 1.21 -0. 63 -2.76 -4 . 57 -6.46 -11.19 0.19 0.25 0.56 0.66 0.67 0.93 0.17 0.17 0.18 0.25 0.40 0.90 4 4 4 4 4 4 5 5 5 5 5 233795 Table 3 (continued! SKgrnple PgSS (jAg/kg) £ B,P. (%) ML A Sodium* JUL 0.100 -1.35 6 -0.28 5 0.300 -4.87 6 0.01 5 1.000 -8.03 6 -0.01 5 3.000 -10.20 6 0.29 5 .000 -15.67 6 0.62 5 .000 -22.23 6 0.74 5 26 0.100 -1.20 13 0.09 9 0.300 -0.79 13 0.41 9 1.000 -0.63 13 0.52 9 3.000 -1.55 13 0.60 9 10.000 -3.58 13 0.58 9 30.000 -6.83 13 0.58 9 27 0.100 -2.48 10 -0.03 9 0.300 -4.85 10 -0.07 9 1.000 -9.20 10 0.03 ' 9 3.000 -11.32 10 0.06 9 10.000 -15.77 10 0.24 9 30.000 -18.54 10 0.49 9 31 0.100 -0.28 6 0.07 5 0.300 -1.93 6 0.32 5 1.000 -3.55 6 0.37 5 3.000 -3.43 6 0.38 5 .000 -4.03 6 0.46 5 .000 -7.18 6 0.49 5 233795 Table 3 (continued! Example Dose
Claims (14)
1. A compound of the formula: r1-r2-r3-r4-r5-r6-r7-r8 or a pharmaceutically acceptable salt, ester or amide thereof, wherein R1 is selected from hydrogen, AcetylArg, Aha, Arg, Cit, His, Lys, Orn and Ser-Ser; 2 R is a sulfur-containing group; is a hydrophobic amino acid or dipeptide; 4 R is a dipeptide spacer or a tripeptide of the formula X-Y, where X is a dipeptide spacer and Y is a basic amino acid; R^ is a hydrophobic amino acid; g R is a peptide of up to three amino acids; 7 R is selected from Cha, Phe, Cha-Arg, Phe-Arg, (D)Phe-Arg, Phe- (D) Arg, Phe^Arg, Leu-Arg, Ala-Arg, Arg and Gly-Ala; and Q R is a sulfur-containing group. -73- 233795
2. The compound of Claim 1 wherein R^" is a basic amino 3 acid; R is a hydrophobic amino acid containing a cycloalkyl; g and R is a peptide of up to three amino acids containing an acidic amino acid.
3. The compound of Claim 1 wherein R1 is hydrogen; R2 is 3 mercaptopropionic acid; R is a hydrophobic amino acid containing a cycloalkyl; and R is a peptide of up to three amino acids containing an acidic amino acid.
4. A compound selected from the group consisting of: Arg-Cys-Cha-(D)Ala-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Ser-Ser-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Cha-Arg-Cys; Arg-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-(D)Ala-Cha-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Cha-Gly-Gly-(D)Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-1le-Phe-Arg-Cys ; Cys-Arg-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; -74- 23 37 Arg-Cys-Cha-(D)Ala-Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Tic-Gly-Gly-Arg-Ile-Asp-Arg-Ile-?he-Arg-Cys-NH2; Arg-Cys-Phe-Gly-Gly-Ile-Asp-Arg-Ile-Phe-Arg-CyS-NH2; His-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Phe-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-CyS-NH2; Orn-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; AcetylArg-Cys-Cha-Gly-Gly-Arg-1le-Asp-Arg-1le-Phe-Arg-Cys-NH2 ; Cit-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Cys-NH2; Arg-Cys-3,5-I2Tyr-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-CySrNH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Lys-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-(D)Asp-Arg-Ile-Phe-Arg-Cys-NH2; (D)Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Chg-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; 23 37 -75- Arg-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ala-Phe-Arg-Cys-NH2; Arg-Cys-(D)Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Arg-Cys-Cha-Gly-Gly-Arg-Ile-Ala-Arg-Ile-Ala-Arg-Cys; Mpa-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-CyS-NH2; Arg-Cys-Cha-Gly-Gly-(D> Arg-I le-Asp-Arg-1le-Phe-Arg-Cys; Arg-Cys-Pic-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys; Cys-Cha-Gly-Gly-Arg-Ile-(D)Asp-Arg-Ile-Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ala-Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Ala-Ile-Phe-Arg-Cys-NH2; Mpa-Cha-Gly-Gly-Arg-Ile-beta-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-(D)Ile-Phe-Arg-Cys-NH2; Cys-Cha-Gly-Gly-Arg-Nva-Asp-Arg-Nva-Phe-Arg-Cys-NH2; Cys-(D)Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Mpa-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-(D)Arg-Cys-NH2; Mpa-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-(D)Cys-NH2; 233795 -76- Mpa-Cha-(D)Ala-Arg-Arg-Ile-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Cys-Phe-Gly-Gly-Arg-Leu-Asp-Arg-Ile-Leu-Arg-Cys-NH2; Mpa-Cha-Gly-Gly-Arg-Ile-Glu-Arg-Ile-Phe-Arg-CyS-NH2; Mpa-Cha-Gly-Gly-(D)Arg-Iie-Asp-Arg-Ile-Phe-Arg-Cys-NH2; Mpa-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-(D)Phe-Arg-Cys-NH2; Aha-Cys-Cha-(D)Ala-(D)Ala-Arg-Ile-Asp~Arg-Ile-Phe-Arg-Cys-NH2; Mpa-Cha-Gly-Gly-Arg-lie-His-Arg-Ile-Phe-Arg-CyS-NH2; Mpa-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Phe-Arg-CyS-NH2; Mpa-Cha-(D)Ala-Ala-Arg-Ile-Asp-Arg-Ile-Phe-Arg-(D)Cys-NH2; and Mpa-Cha- (D) Ala-Ala-Arg-Ile-Asp-Arg-Ile- [Phe^Arg] - (D) Cys-NH2 ; or a pharmaceutically acceptable salt, ester, or amide thereof.
5. A pharmaceutical composition comprising a therapeutically effective amount of the compound of Claim 1 and a pharmaceutically acceptable carrier or a diluent. /.53/yo -77-
6. Use of a compound of claim 1 in the preparation of a medicament suitable for use in producing natriuresis.
7. Use of a compound of claim 1 in the preparation of a medicament suitable for use in producing diuresis.
8. Use of a compound of claim 1 in the preparation of a medicament suitable for use in producing renovasodilation.
9. Use of a compound of claim 1 in the preparation of a medicament suitable for use in providing renoprotection.
10. Use of a compound of claim 1 in the preparation of a medicament suitable for use in treating ANP-related disorders.
11. use according to Claim 10 in which the ANP-related disorder is selected from hypertension, renal failure, cerebral edema, congestive heart failure and cirrhosis.
12. A compound as claimed in claim 1 or a pharmaceutically acceptable salt, ester or amide thereof, and substantially as herein described with reference to any embodiment disclosed in the examples.
13. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 12 and a pharmaceutically acceptable carrier or diluent.
14. Use as claimed in any one of claims 6 to 11 and substantially as herein described with reference to any embodiment disclosed in the examples. * ./q&So-rr;* to JUN!992^J ■ > , q/-' pe"
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35698089A | 1989-05-24 | 1989-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ233795A true NZ233795A (en) | 1992-07-28 |
Family
ID=23403792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ233795A NZ233795A (en) | 1989-05-24 | 1990-05-24 | Derivatives of atrial natriuretic peptide (anp) |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0431113A4 (en) |
JP (1) | JPH04500363A (en) |
KR (1) | KR920701244A (en) |
AU (1) | AU5827690A (en) |
CA (1) | CA2033198A1 (en) |
GR (1) | GR1001018B (en) |
IL (1) | IL94487A0 (en) |
NZ (1) | NZ233795A (en) |
WO (1) | WO1990014362A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208218A (en) * | 1988-09-19 | 1993-05-04 | Ludwig Institute For Cancer Research | T cell growth factor glycoproteins |
US6525022B1 (en) | 1993-11-12 | 2003-02-25 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US5665704A (en) * | 1993-11-12 | 1997-09-09 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
US5846932A (en) * | 1993-11-12 | 1998-12-08 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
JP2006514607A (en) * | 2002-07-31 | 2006-05-11 | コンジュケム,インコーポレーテッド | Long-lasting sodium excretion increasing peptide derivative |
US8580746B2 (en) | 2006-03-30 | 2013-11-12 | Palatin Technologies, Inc. | Amide linkage cyclic natriuretic peptide constructs |
WO2007115182A2 (en) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Linear natriuretic peptide constructs |
WO2007115175A2 (en) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
WO2011098095A1 (en) * | 2010-02-09 | 2011-08-18 | Aplagen Gmbh | Peptides binding the tpo receptor |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU597919B2 (en) * | 1985-11-05 | 1990-06-14 | Scios Nova Inc. | Analogs of atrial natriuretic peptides |
US4757048A (en) * | 1985-11-05 | 1988-07-12 | Biotechnology Research Associates J.V. | Synthetic analogs of atrial natriuretic peptides |
US4721704A (en) * | 1986-05-09 | 1988-01-26 | Peninsula Laboratories, Inc. | Potent synthetic atrial peptide analogs |
US4804650A (en) * | 1986-10-28 | 1989-02-14 | Biotechnology Research Associates, J.V. | Analogs of atrial natriuretic peptides |
EP0271041A3 (en) * | 1986-12-10 | 1990-04-11 | Abbott Laboratories | Atrial peptide derivatives |
EP0292256A3 (en) * | 1987-05-19 | 1990-10-03 | Merck & Co. Inc. | Peptides having anf activity |
US4935492A (en) * | 1987-12-24 | 1990-06-19 | California Biotechnology Inc. | Cyclic analogs of atrial natriuretic peptides |
-
1990
- 1990-05-23 CA CA002033198A patent/CA2033198A1/en not_active Abandoned
- 1990-05-23 KR KR1019910700087A patent/KR920701244A/en not_active Application Discontinuation
- 1990-05-23 JP JP2508785A patent/JPH04500363A/en active Pending
- 1990-05-23 GR GR900100396A patent/GR1001018B/en unknown
- 1990-05-23 AU AU58276/90A patent/AU5827690A/en not_active Abandoned
- 1990-05-23 EP EP19900909101 patent/EP0431113A4/en not_active Withdrawn
- 1990-05-23 WO PCT/US1990/002917 patent/WO1990014362A1/en not_active Application Discontinuation
- 1990-05-24 NZ NZ233795A patent/NZ233795A/en unknown
- 1990-05-24 IL IL94487A patent/IL94487A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
GR1001018B (en) | 1993-03-31 |
KR920701244A (en) | 1992-08-11 |
IL94487A0 (en) | 1991-03-10 |
EP0431113A4 (en) | 1992-01-22 |
WO1990014362A1 (en) | 1990-11-29 |
JPH04500363A (en) | 1992-01-23 |
EP0431113A1 (en) | 1991-06-12 |
AU5827690A (en) | 1990-12-18 |
CA2033198A1 (en) | 1990-11-25 |
GR900100396A (en) | 1991-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI91075C (en) | Process for the preparation of novel therapeutically useful peptides | |
US4766108A (en) | Tyr-Arg-vasopressin antagonists | |
US20030050436A1 (en) | Octapeptide bombesin analogs | |
HRP970630A2 (en) | Hepapeptide oxytocin analogues | |
US5106834A (en) | Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents | |
CZ281507B6 (en) | Synthetic peptides, biologically active fragment and said peptide non-toxic salts | |
SK308692A3 (en) | Cyclic vasoactive peptides | |
EP0363589A2 (en) | Somatostatin analogues | |
JPH0684400B2 (en) | Novel growth hormone-free peptide | |
US4659691A (en) | Novel cyclic Hexapeptide LHRH antagonists | |
WO1997042223A9 (en) | hGH-RH(1-29)NH2 ANALOGUES HAVING ANTAGONISTIC ACTIVITY | |
NZ233795A (en) | Derivatives of atrial natriuretic peptide (anp) | |
EP0341603A2 (en) | Atrial peptide derivatives | |
EP0269299A2 (en) | Atrial peptides | |
JP2927936B2 (en) | Peptides | |
US4481193A (en) | Des-proline vasopressin antagonists | |
EP0271041A2 (en) | Atrial peptide derivatives | |
US4599324A (en) | V1-vasopressin antagonists | |
US4684622A (en) | Compositions and methods for producing vasodilation and antioxytocic activity | |
NO854645L (en) | PROCEDURE FOR THE PREPARATION OF BASIC CYCLIC PEPTIDES. | |
US5091366A (en) | Peptides having ANF activity | |
US4597901A (en) | β-indolylalanyl or β-indolylglycinyl vasopressin antagonists | |
US4876243A (en) | Vasopressin compounds | |
FI91413B (en) | Process for the preparation of pharmaceutically useful CRF analogues | |
AU613364B2 (en) | Novel alkylated growth hormone-releasing peptides and method of treating mammals therewith |